Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00269399 · ClinicalTrials.gov registry record · Phase 3
A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 237
- Enrollment target
NCT00269399 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 237 participants.
The verdict
NCT00269399, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 237 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).
Interventions
- DRUG Vancomycin
- DRUG Rifaximin (Xifaxan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00269399
The ClinicalTrials.gov registry entry for NCT00269399 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vancomycin is the first listed.
NCT00269399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00269399 about?
NCT00269399 is a clinical study titled "A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)". The purpose of this study is to assess the treatment and safety of a 10-day course of rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium difficile-associated diarrhea (CDAD).
What is the current status of trial NCT00269399?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 237 participants. The study started on 2005-12. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00269399?
The interventions under investigation include: Vancomycin (DRUG), Rifaximin (Xifaxan) (DRUG).
Who is sponsoring clinical trial NCT00269399?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.